Your browser doesn't support javascript.
loading
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).
Mease, Philip J; Gladman, Dafna D; Samad, Ahmed S; Coates, Laura C; Liu, Lyrica X H; Aras, Girish A; Collier, David H; Chung, James B.
Afiliación
  • Mease PJ; Rheumatology Clinical Research Division, Swedish Medical Center and Division of Rheumatology, University of Washington, Seattle, Washington, USA.
  • Gladman DD; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Samad AS; US Medical Organization, Amgen Inc., Thousand Oaks, CA, USA.
  • Coates LC; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Liu LXH; Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
  • Aras GA; Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
  • Collier DH; US Medical Organization, Amgen Inc., Thousand Oaks, CA, USA.
  • Chung JB; US Medical Organization, Amgen Inc., Thousand Oaks, CA, USA.
RMD Open ; 4(1): e000606, 2018.
Article en En | MEDLINE | ID: mdl-29531787
OBJECTIVE: To evaluate the efficacy of etanercept and methotrexate as monotherapies and as combination therapy in subjects with active psoriatic arthritis (PsA). METHODS: The Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) is an ongoing, global, double-blind, 48-week, randomised, controlled study. Subjects are randomised (1:1:1) to etanercept monotherapy, methotrexate monotherapy or etanercept-methotrexate combination therapy. Endpoints include rates of ACR20 response and Minimal Disease Activity, measures to characterise extra-articular manifestations (dactylitis, enthesitis, nail disease) and safety. CONCLUSION: SEAM-PsA will characterise the effects of etanercept with and without background methotrexate and methotrexate alone on PsA manifestations, and provide information of practical importance to clinicians on the optimal treatment of PsA.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: RMD Open Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: RMD Open Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido